PubMed Health⌕ Search

Biomedical subjects

N Itagaki

Publications and source records attributed to N Itagaki.

11 recordsLinked to original sources
PubMed2004

Equilateral-triangular shape in 14C.

An equilateral-triangular shape of three alpha clusters surrounded by excess neutrons is suggested for 14C, based on the molecular-orbit model. It is found that the attractive interaction between an excess neutron and an alpha particle stabilizes the K(pi)=0(+) and 3(-) rotational bands, which demonstrates an equilateral-triangular symmetry. This K(pi)=3(-) band at 3 MeV below the 10Be+alpha threshold energy corresponds to the experimentally observed band built on top of the second 3(-) state. A positive-parity rotational band (0(+), 2(+), 4(+)) arises similarly. These two bands suggest a molecular 3-alpha structure stabilized by the excess neutrons and can be viewed as a realization of the alpha crystallization in the dilute nuclear medium.

Journal Article↗
PubMed1992

[A case of Vibrio cholerae non-O1 septicemia with liver cirrhosis].

A case of Vibrio cholerae non-O1 septicemia is described in this paper. A 45-year-old male with a three year history of liver cirrhosis, was admitted to our division with hematemesis, abdominal pain, high fever and a loss of consciousness. Three days before onset of symptoms, he traveled to Ishigaki Island and ate a raw lobster. Two days after, his temperature rose to 39.7 degrees C and the blood pressure dropped to 36/- mmHg. By endoscopic examination, an ulcer was found in the stomach, and the bleeding was stopped by electrical coagulation. Blood culture showed growth of V. cholerae non-O1. The organism was found to be sensitive to OFLX, CZX, MINO, LMOX and CP. Although DIC, infections of fungus and MRSA occurred as complications, he recovered by adequate procedures. Subsequently, he left this division after eight weeks. There are various reports related to V. cholerae non-O1 septicemia in foreign countries, but few cases have been reported in Japan. And these cases had severe underlying diseases such as leukemia and liver cirrhosis.

Bacteremia↗
PubMed1991

[Pharmacokinetics of cefodizime in patients undergoing hemodialysis].

The object of this study was to establish the most effective regimen of cefodizime (CDZM) for patients with chronic renal failure undergoing hemodialysis (HD). T 1/2 beta of CDZM upon 1 g intravenous administration was 3.50 +/- 0.72 hours in an on-HD group, and it was 11.26 +/- 3.89 hours in an off-HD group. When CDZM was administered consecutively at a dose of 1 g or 2 g only after HD, the serum concentration of CDZM was maintained at levels sufficient to exert antibacterial activity, and no tendency for accumulation was observed. The most effective regimen of CDZM to HD patients, therefore, has been that in which concluded to administration was done only after completion of HD, in a dose of 1 g for mild infections and that of 2 g for severe infections.

Cefotaxime↗
PubMed1988

[Pharmacokinetics of cefmenoxime in renal-failure patients undergoing continuous arteriovenous hemofiltration].

We investigated the pharmacokinetics of cefmenoxime (CMX) administrated to renal-failure patients undergoing continuous arteriovenous hemofiltration (CAVH). CAVH was carried out with a filter (0.5 m2) employing a PAN-50P (hollow fiber type) made of polyacrylonitrile membrane, with a blood flow rate of 100 ml/min and a filtration rate of 1,200 ml/hr. At 5 and 300 minutes after the CMX administration, the concentrations of CMX in the serum were 126.8 mg/L and 31.5 mg/L, respectively. The T1/2 beta was 3.55 hours. In 300 minutes after the administration of CMX, the total amount of CMX contained in the filtrate corresponded to 11.6% of the administered dose.

Acute Kidney Injury↗
PubMed1988

[Pharmacokinetics of cefotiam in patients undergoing continuous ambulatory peritoneal dialysis].

The pharmacokinetics of cefotiam (CTM) was investigated in 7 patients undergoing continuous ambulatory peritoneal dialysis (CAPD). One gram of CTM was infused either intravenously (i.v. group) or intraperitoneally (i.p. group). In the i.v. group, the serum concentration of CTM at 6 hours after infusion was 25.9 mg/L and the half-life value was 5.09 hours, while the peak value of CTM in dialysate was 12.4 mg/L. In the i.p. group without peritonitis, the dialysate concentration of CTM at 6 hours after infusion was 108.6 mg/L. The serum concentration at 15 minutes after infusion was 3.0 mg/L, the corresponding peak value was 14.0 mg/L at 4 and 6 hours after infusion.

Adult↗